Company
Headquarters: Guildford, United Kingdom
Employees: 13
CEO: Mr. James Henry Barder
£7.3 Million
GBP as of Jan. 1, 2026
US$9.8 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Futura Medical plc, a pharmaceutical company, researches and develops pharmaceutical drugs and medical devices for the consumer healthcare markets focusing on sexual health and pain relief management. The company offers CSD500, a condom that contains erectogenic gel. It is also developing MED3000, a topical gel for the treatment of erectile dysfunction that has completed Phase III clinical trials. In addition, the company develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | £3.1 M |
| EBITDA | £-6,833,498 |
| Gross Profit TTM | £1.8 M |
| Profit Margin | -210.03% |
| Operating Margin | -358.11% |
| Quarterly Revenue Growth | % |
Futura Medical plc has the following listings and related stock indices.
Stock: LSE: FUM wb_incandescent
Stock: FSX: GYX wb_incandescent
Stock: OTC: FAMDF wb_incandescent